Usa Britain city Oxford hospital covid-19 recommendations patient Coronavirus Usa Britain city Oxford

Study: HIV drug of no benefit to hospitalized COVID patients

Reading now: 569
www.cidrap.umn.edu

The combination drug lopinavir-ritonavir is not recommended for hospitalized COVID-19 patients because it doesn't significantly shorten hospital stay or lower the risk of needing mechanical ventilation or of dying, according to a study yesterday in The Lancet.The ongoing University of Oxford–sponsored Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial involving coronavirus patients at 176 hospitals in the United Kingdom is the first known large, randomized, controlled trial to assess the effectiveness of lopinavir-ritonavir for this indication.The antiviral drug combination, approved by the US Food and Drug Administration to treat HIV/AIDS, has been recommended as a first- or second-line treatment for COVID-19 in many countries on

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA